Disclosure of financial information

Collaboration between healthcare professionals and pharmaceutical companies has had a positive impact on the development of treatments and medicines. These parties often collaborate on research and education, for the benefit of patients.

By implementing ethical codes, pharmaceutical companies and healthcare professionals have worked to strengthen the rules on which their collaboration is based. The public should be able to trust that such collaboration does not influence clinical decisions and that healthcare professionals advise, provide or purchase appropriate treatments and services based solely on clinical findings and experience.

Since 2016, EFPIA member companies and Frumtaka, along with other pharmaceutical companies, have begun publishing an annual report with information on payments for collaboration with healthcare professionals and healthcare institutions.

The EU Commission has issued rules on promoting good governance in the pharmaceutical industry, which were agreed by all stakeholders in 2013. These rules require that information on certain payments be made public.

EFPIA, Frumtok member companies and other pharmaceutical companies support these rules. The rules stipulate that, starting in 2016, information on payments to healthcare professionals and institutions from the previous year will be published annually. Payments covered by the rules include, for example, grants to healthcare institutions, consultancy fees for lectures, travel and accommodation costs and registration fees for conferences. This information will be published on Frumtok's website, www.frumtok.is or on another website determined by the company.

The goal is to strengthen collaboration between pharmaceutical companies and healthcare professionals by making it more transparent for patients and other stakeholders. We look forward to continuing to work to improve the quality of treatments, research, and overall patient care.

By implementing the Code of Ethics, pharmaceutical companies and healthcare professionals have worked to strengthen the rules on which their collaboration is based. The public should be able to trust that such collaboration does not influence clinical decisions and that healthcare professionals advise, provide or purchase appropriate treatments and services based solely on clinical findings and experience. The aim is to strengthen the collaboration between pharmaceutical companies and healthcare professionals by making it more transparent for patients and other stakeholders. We look forward to continuing to work to improve the quality of treatments, research and general patient care. EFPIA, Frumtök and all our member companies support these rules on disclosure of information. The rules require all member companies to disclose information about payments to healthcare professionals and institutions.